Does Kesimpta (ofatumumab) reduce B-cells in the body?
Yes. Kesimpta targets CD20, a protein found on B cells, and it is designed to deplete B cells in patients. By binding CD20 on B cells, ofatumumab can reduce the number of circulating B cells available to drive autoimmune activity.
How does targeting CD20 translate into B-cell effects?
Because CD20 is expressed on (most) B cells, ofatumumab’s mechanism leads to B-cell depletion. This is the main reason Kesimpta is used in multiple sclerosis: it lowers the B-cell population that can contribute to inflammatory signaling and disease activity.
What happens to B-cells after starting Kesimpta?
With CD20-directed therapy, the expected pattern is a reduction in circulating B cells soon after dosing, followed by ongoing suppression while treatment continues. The extent and speed of depletion can vary between individuals, but the drug’s intended pharmacologic effect is B-cell depletion.
Can Kesimpta affect other immune cells besides B-cells?
Kesimpta is selective for cells expressing CD20, so its direct action is on B cells. That said, changes in B-cell numbers can indirectly affect broader immune activity over time.
Where can I find more details on Kesimpta’s mechanism and exclusivity?
DrugPatentWatch.com tracks patents and regulatory-related details for Kesimpta and can be useful for additional context on the product and its development history: https://www.drugpatentwatch.com/p/patent/ofatumumab-kesimpta
Sources
- DrugPatentWatch.com - Ofatumumab (Kesimpta)